Discovery of novel antitumor sulfonamides targeting G1 phase of the cell cycle

Area of Science:

• Oncology
• Medicinal Chemistry
• Cell Biology

Background:

• Cell cycle regulation, particularly the G1 phase, is critical in cancer research due to its role in cell proliferation and apoptosis.
• Previous work identified E7010, an antitumor sulfonamide inhibiting tubulin polymerization.
• Structurally related compounds were investigated for novel anticancer mechanisms.

Purpose of the Study:

• To discover novel antitumor sulfonamides targeting the G1 phase of the cell cycle.
• To identify compounds with significant antitumor activity against cancer cell lines and xenografts.
• To characterize the mechanism of action of promising drug candidates.

Main Methods:

• Synthesis and screening of a novel series of sulfonamide compounds.
• In vitro cell proliferation assays using HCT116 human colon carcinoma cells.
• In vivo efficacy studies in nude mice bearing human tumor xenografts.
• Cell cycle progression analysis in P388 murine leukemia cells.

Main Results:

• A new class of sulfonamides was identified that blocks cell cycle progression specifically in the G1 phase.
• N-(3-chloro-7-indolyl)-1,4-benzenedisulfonamide (E7070) demonstrated potent in vitro activity (IC50 0.11 microg/mL) against HCT116 cells.
• E7070 exhibited significant in vivo antitumor effects, including tumor growth suppression and size reduction in xenograft models.
• E7070 does not inhibit M phase progression.

Conclusions:

• E7070 represents a promising novel antitumor agent with a unique G1 cell cycle arrest mechanism.
• The compound shows significant efficacy against human colon carcinoma xenografts.
• E7070 is currently advancing through Phase I clinical trials in Europe based on its preclinical profile.